| Purpose | Announcement Date | Ex-Date | Record Date | Dividend Amount | Dividend per Share | Remark |
|---|---|---|---|---|---|---|
| Dividend | 14 May 2025 | 16 Jul 2025 | 16 Jul 2025 | 0.14 | 1.4 | Final |
| Please refer attachment The Board of Directors has recommended a final dividend of Rs. 0.14/- per Equity Share of Rs. 10/- each for the financial year ended 31st March 2025, which will be paid / dispatched after the 5th Annual General Meeting, subject to the approval of shareholders of the Company. Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company has fixed Wednesday, 16th July, 2025 as the Record Date for the purpose of determining the Members eligible for Final Dividend for the financial year ended 31st March, 2025. If the Final Dividend, as recommended by the Board of Directors, is approved at the AGM, such dividend will be paid/dispatched, subject to deduction of tax at source, after the AGM. (As per BSE Announcement Dated on 13/06/2025) | ||||||
The company stated in its filing with the bourses that its remains committed to maintain highest compliance standards.
Piramal Critical Care has reserved commercialisation rights for the EU, UK, and Norway and will look after Neoatricon in these regions.
This month, the US FDA inspected the facility and after inspection issued a Form 483 of six observations as the company has to improve compliance in this regard.
In response to growing demand of IA, capacity expansions are under way at both Dahej and Digwal facilities, with month-on-month production growth.
As part of long-term strategy PCC has seen a number of product launches during recent times which are building block towards market presence in generic injectables.
The transaction falls in the internal transaction category because the parent is trading with a subsidiary.
Piramal Pharma Solutions (PPS) is set to invest $80 million in expanding its sterile injectables facility in Lexington, Kentucky, USA, projected for completion by FY27.
Piramal Pharma Limited's Chairperson, Nandini Piramal, attributed the company's development to its solid operational performance.
On September 11, 2024, and October 26, 2023, the stock reached a 52-week high of ₹244.10 and a low of ₹87.55.
Here are some of the stocks that may see significant price movement today: HCL Technologies, Lupin, Piramal Pharma, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
